Skip to content
Medical Health Aged Care, Women

The silent crisis no one talks about: ‘On The Down Low’ podcast returns to raise awareness of one of Australia’s fastest growing women’s cancers

Australia New Zealand Gynaecological Oncology Group (ANZGOG) 3 mins read

MEDIA RELEASE 
Thursday 18 September 2025  

The silent crisis no one talks about: ‘On The Down Low’ podcast returns to raise awareness of one of Australia’s fastest growing women’s cancers 

Uterine cancers (including endometrial cancer) are the fastest growing women’s cancer in Australia, yet they remain largely unknown, underfunded, and under-researched. Each year, close to 3,500 women are diagnosed and tragically close to 800 women lose their lifei. Projections indicate this is significantly on the rise with more than 74,000 new cases and 8,900 deaths in the next decade¹. 

To address the silent crisis for women that is not being talked about, the Australia New Zealand Gynaecological Oncology Group (ANZGOG), the peak national gynaecological cancer research organisation, is dedicating Season 2 of its award-winning podcast On The Down Low – Speaking Up About Gynaecological Cancer to uterine cancers, the most common type of gynaecological cancer. 

Hosted by journalist Alison Dance, the six-part series blends raw lived-experience stories with expert medical insights, covering symptoms, diagnosis, treatment, survivorship and advocacy. Each episode encourages women to speak up, ask questions, and explore options for better outcomes—while providing hope for those who, unlike with other cancers, often lack a community to turn to. 

Although uterine cancers have traditionally been diagnosed in mature women, incidence rates are now rising sharply, particularly among women aged 30 to 50, said Professor Alison Brand AM, ANZGOG Director, Research Advisory Committee. 

“Through honest and intimate conversations, we are breaking the silence, shining a light on this urgent issue, and raising awareness of a disease that demands greater knowledge, support, and funding,” Ms Brand said. 

About Uterine Cancers: 

  • Uterine cancer incidence has doubled over the past 20 years and continues to rise, increasingly affecting women aged 30–50. 

  • Women in regional, remote, and rural areas, women from lower socioeconomic backgrounds, and Aboriginal and Torres Strait Islander women face higher incidence and mortality rates. 

  • Unlike breast, ovarian, blood or lung cancers, there is no dedicated support organisation for uterine cancer, leaving close to 3,500 women expected to be diagnosed this year without comprehensive survivorship and supportive care. 

  • By sharing lived experiences and expert knowledge, the podcast addresses this critical gap and highlights the urgent need for research, advocacy, and systemic change. 

‘On The Down Low’ Season 2: Episode overview and launch dates: 

  • S2.E1: Prevention, Risk and Early Diagnosis (from 18 Sept) – Understanding early warning signs, risk factors, and genetic predispositions 

  • S2.E2: Surgery and Fertility Considerations (from 24 Sept) – Exploring surgical options and fertility-sparing treatments. 

  • S2.E3: Research, Treatment and Epidemiology (from 1 Oct) – Emerging therapies, clinical trials, and rising incidence trends. 

  • S2.E4: Challenges of Rare Uterine Cancers (from 8 Oct) – Highlighting rare subtypes, misdiagnosis, and gaps in research. 

  • S2.E5: Survivorship and Rehabilitation (from 15 Oct) – Addressing physical, emotional, and identity recovery, alongside tailored support needs. 

  • S2.E6: Advocacy: What Women Need to Know (from 22 Oct) – Amplifying patient voices, tackling stigma, and driving policy and funding reform. 

Season 2 is produced by ANZGOG, with the generous support of GSK and Eisai. Listen via Apple Podcasts [link] and Spotify [link]. 

Help Break the Silence: By listening, sharing, and starting conversations about uterine cancers, you can help raise awareness, advocate for equitable support, and drive urgently needed change. Learn more at anzgog.org.au.  

Content Warning: This podcast contains personal stories. It is not a substitute for professional medical advice. If you are concerned about your health, contact a healthcare professional or the Cancer Council Information Line on 13 11 20.  

#OnTheDownLowPodcast #UterineCancer #EndometrialCancer #GynaecologicalCancer  

ENDS 

 

About us:
 

About Australia New Zealand Gynaecological Oncology Group (ANZGOG):  

ANZGOG is the peak national gynaecological cancer research organisation in Australia and New Zealand. We foster and lead innovative, world-class multidisciplinary research to improve outcomes and quality of life for everyone with a lived experience of gynaecological cancer.  

Our vision is clear: Advancing research, saving lives. 

For over 26 years, ANZGOG has enabled over 60 clinical trials across all types of gynaecological cancer, involving more than 4,500 patients. These trials are delivered through over 80 hospital sites, supported by both local and global research collaborations. Our growing network includes over 1,500 members across clinical, allied health, and pure research disciplines—alongside community representatives who ensure the voices of women with lived experience are at the centre of everything we do. 


Contact details:

For media interviews or more information, please contact: Monique Cerreto: T: 0416 282 464, E: [email protected] 

Media

More from this category

  • Indigenous, Medical Health Aged Care
  • 26/03/2026
  • 10:00
Charles Darwin University

CDU EXPERT: Fuel crisis causing inequitable access to health care and food security

26MARCH,2026 Who:ProfessorofIndigenous HealthYvette Roe,Directorof theMollyWardagugaInstitute for First Nations Birth RightsatCharles DarwinUniversity. Topics: Rising fuel prices and the impact this will have on food security and the health and well-being of mums and bubs Food security Contact details:Call +61 8 8946 6721 or email [email protected] to arrange an interview. Quotes attributable toProfessorYvette Roe: “Aboriginal women and girls in this in our remote Territory communities experience some of the poorest sexual, reproductive, maternal, infant, and child health outcomes in Australia (e.g. preterm birth rates are regularly the highest in the country at 18-22%). Acute poverty, overcrowding, limited employment opportunity and food security are keysocio-economic determinants for a thriving mother and babyduringacross the lifecourse. “Mums andbabies whorequireregular check-ups, antenatal care, and access to nutritious food and prenatal vitamins are most at risk…

  • Government Federal, Medical Health Aged Care
  • 26/03/2026
  • 06:10
Australian College of Nursing

Let nurse practitioners lead Urgent Care Clinics to address staffing issues

The Australian College of Nursing is calling on the Federal Government to revise guidelines to allow nurse practitioners to lead care independently in Medicare Urgent Care Clinics (UCCs), with GP recruitment an ongoing challenge for the program. Nurse practitioners are among the most highly qualified clinicians in our health system, capable of leading UCCs, but the current Medicare Urgent Care Clinic Program Operational Guidance mandates that clinics will be GP-led, with a vocationally registered general practitioner required at a minimum. The latest evaluation of the program noted recruitment of appropriately qualified doctors remains an issue, and that Medicare Benefits Schedule…

  • Contains:
  • Medical Health Aged Care
  • 26/03/2026
  • 06:00
Monash University

New medicine piggybacks onto fat absorption pathways to allow oral delivery and support clinical trial in major depressive disorder

Monash University and Seaport Therapeutics have developed a new approach to delivering drug molecules that piggybacks onto natural fat absorption pathways to allow oral delivery of some drugs previously requiring injection. The research, published today inScience Translational Medicine, describes the first clinical evidence that a fat, or lipid, modified version of the naturally occurring neurosteroid allopregnanolone (GlyphAllo™) can result in high enough levels of the substance in the human bloodstream to be potentially effective. The endogenous neurosteroid allopregnanolone is a well-established molecule known for its clinically validated antidepressant, anti-anxiety and sleep-promoting effects – but to this point had to be…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.